<DOC>
	<DOCNO>NCT00809393</DOCNO>
	<brief_summary>Cardiac surgery CardioPulmonary Bypass ( CPB ) expose per postoperative bleeding , may lead allogenic blood transfusion re-intervention many adverse outcome . Prophylactic use tranexamic Acid ( TA ) show decrease blood loss blood transfusion cardiac surgery.There currently multiple dose regimen TA cardiac surgery.Preliminary dose-response study show low prophylactic dose TA would accurate haemostatic efficacy high dose . The primary objective tri-center , prospective , double-blinded , randomised trial compare two administration dose regimen TA cardiac surgery CPB perioperative blood loss . In addition clinical study , pharmacokin√©tic/pharmacodynamic study conduct . Patients divide two group : low high risk surgery . Methods : After write informed consent , patient randomly assign one two treatment group . The low dose TA group : 10 mg/kg TA give 15 min , follow infusion 1 mg/kg/h throughout operation , 1 mg/kg CPB prime volume . The high dose group :30 mg/kg TA give 15 min , follow infusion 16 mg/kg/h throughout operation , 2 mg/kg CPB prime volume . Hemodynamic anaesthesia care usual . A blood salvage device systematically use . The trigger transfusion : red blood cell : haemoglobin le 8 g/dl 6 g/dl CBP ; Plasma : PT le 50 % INR 1.5 ; platelet : platelet count less 50/70 G/mm3 ; fibrinogen : fibrinogen le 1g/l . All patient receive standard anaesthesia perioperative care . In 60 consecutive patient principal investigator center , 5 blood sample allow assess plasmatic concentration tranexamic acid different time surgery procedure : 1 . Baseline 2 . 5 min load dose 3 . 10 min begin bypass 4. discontinuation infusion 5 . 1 hour discontinuation Plasmatic dosage assess use high performance liquid chromatography technique . Patients stratify two group statistical analysis ; low high risk surgery . Analysis intention treat . 300 patient recruit group detect absolute difference respectively 10 % ( low risk cardiac surgery ) 20 % ( high risk cardiac surgery ) number patient expose allogenic blood transfusion patient receive high dose TA regimen receive low dose TA regimen , assume power 80 % two-tailed value less 0.05 .</brief_summary>
	<brief_title>Dose-ranging Study Two Doses Tranexamic Acid During Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Any type cardiac surgical procedure require CPB ( include coronary artery bypass grafting , valve repair replacement , aortic surgery , endocarditis ) . Emergency surgery , age &lt; 18 year old , pregnancy , history allergy TA , history seizure thromboembolism event , history previous antifibrinolytic thrombolytic therapy within 5 day surgery , coagulation disorder , liver disease , renal failure ( clearance &lt; 30 ml/min ) , Jehovah witness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Antifibrinolytic</keyword>
	<keyword>Tranexamic acid</keyword>
	<keyword>Cardiopulmonary bypass</keyword>
	<keyword>Transfusion</keyword>
	<keyword>Hemorrhage</keyword>
</DOC>